David Warr

9.3k total citations · 2 hit papers
103 papers, 6.4k citations indexed

About

David Warr is a scholar working on Surgery, Oncology and Physiology. According to data from OpenAlex, David Warr has authored 103 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Surgery, 36 papers in Oncology and 31 papers in Physiology. Recurrent topics in David Warr's work include Nausea and vomiting management (59 papers), Anesthesia and Pain Management (36 papers) and Pathogenesis and Treatment of Hiccups (21 papers). David Warr is often cited by papers focused on Nausea and vomiting management (59 papers), Anesthesia and Pain Management (36 papers) and Pathogenesis and Treatment of Hiccups (21 papers). David Warr collaborates with scholars based in Canada, United States and New Zealand. David Warr's co-authors include Paul J. Hesketh, Joseph L. Pater, Jean Latreille, Benny Zee, David Osoba, Richard J. Gralla, Fausto Roila, Alexandra D. Carides, Jørn Herrstedt and Steven M. Grunberg and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

David Warr

100 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

2003 593 citations Paul J. Hesketh, Richard J. Gralla et al. Journal of Clinical Oncology profile →
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

2016 397 citations Fausto Roila, Alex Molassiotis et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Warr Canada	41	3.2k	2.0k	1.6k	1.0k	936	103	6.4k
Fausto Roila Italy	45	4.5k 1.4×	1.7k 0.8×	2.0k 1.2×	1.2k 1.2×	980 1.0×	135	7.9k
Karin Jordan Germany	33	2.0k 0.6×	4.1k 2.0×	961 0.6×	606 0.6×	1.4k 1.5×	112	7.4k
Sander M. J. van Kuijk Netherlands	36	2.0k 0.6×	486 0.2×	584 0.4×	782 0.8×	602 0.6×	433	5.6k
Richard J. Gralla United States	64	6.8k 2.1×	6.8k 3.4×	3.1k 1.9×	1.6k 1.5×	5.6k 6.0×	294	16.2k
Barry Laird United Kingdom	39	684 0.2×	1.8k 0.9×	1.9k 1.2×	562 0.6×	657 0.7×	139	4.3k
Alan N. Sandler Canada	32	3.2k 1.0×	637 0.3×	675 0.4×	532 0.5×	868 0.9×	108	5.6k
Gary B. Chisholm United States	38	767 0.2×	1.8k 0.9×	430 0.3×	1.3k 1.3×	555 0.6×	123	6.0k
Paul J. Hesketh United States	51	8.3k 2.6×	2.4k 1.2×	3.9k 2.4×	1.4k 1.4×	1.6k 1.8×	161	11.5k
Simon Van Belle Belgium	32	942 0.3×	1.6k 0.8×	366 0.2×	555 0.6×	495 0.5×	135	4.3k
Antonio Viganò Canada	29	631 0.2×	1.3k 0.6×	1.3k 0.8×	890 0.9×	374 0.4×	69	3.8k

Countries citing papers authored by David Warr

Since Specialization

Citations

This map shows the geographic impact of David Warr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Warr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Warr more than expected).

Fields of papers citing papers by David Warr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Warr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Warr. The network helps show where David Warr may publish in the future.

Co-authorship network of co-authors of David Warr

This figure shows the co-authorship network connecting the top 25 collaborators of David Warr. A scholar is included among the top collaborators of David Warr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Warr. David Warr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bédard, Philippe L., Mihaela Mates, Karen A. Gelmon, et al.. (2020). 19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC). Annals of Oncology. 31. S7–S7. 4 indexed citations

Dranitsaris, George, Carlo DeAngelis, David Warr, & Lutchmie Narine. (2018). Pharmacoeconomic Analysis of Prophylactic Treatments for Emesis Secondary to Breast Cancer Chemotherapy. The Canadian Journal of Hospital Pharmacy. 48(5). 266–275.

Warr, David. (2018). Bringing it all together in the treatment of CINV: application of current knowledge into routine clinical practice. Supportive Care in Cancer. 26(S1). 29–33. 3 indexed citations

Mah, Kenneth, Kim Tran, Lynn R. Gauthier, et al.. (2017). Psychometric Evaluation of the Pain Attitudes Questionnaire-Revised for People With Advanced Cancer. Journal of Pain. 18(7). 811–824. 1 indexed citations

Dranitsaris, George, Alex Molassiotis, Mark Clemons, et al.. (2016). Identifying cancer patients at high risk for chemotherapy-induced nausea and vomiting (CINV): the development of a prediction tool. Annals of Oncology. 27. vi498–vi498. 4 indexed citations

Roila, Fausto, David Warr, Paul J. Hesketh, et al.. (2016). 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy. Supportive Care in Cancer. 25(1). 289–294. 46 indexed citations

Warr, David. (2013). Prognostic factors for chemotherapy induced nausea and vomiting. European Journal of Pharmacology. 722. 192–196. 57 indexed citations

Gauthier, Lynn R., Gary Rodin, Camilla Zimmermann, et al.. (2012). The Communal Coping Model and Cancer Pain: The Roles of Catastrophizing and Attachment Style. Journal of Pain. 13(12). 1258–1268. 34 indexed citations

Vardy, Janette L., Gregory R. Pond, Anna Dodd, et al.. (2012). A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment. 136(1). 143–151. 8 indexed citations

10.

Hesketh, Paul J., David Warr, James C. Street, & Alexandra D. Carides. (2010). Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Supportive Care in Cancer. 19(9). 1297–1302. 10 indexed citations

11.

Stockler, Martin R., Janette L. Vardy, Avinesh Pillai, & David Warr. (2004). Acetaminophen (Paracetamol) Improves Pain and Well-Being in People With Advanced Cancer Already Receiving a Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial. Journal of Clinical Oncology. 22(16). 3389–3394. 81 indexed citations

12.

Roila, Fausto, David Warr, Rebecca Clark-Snow, et al.. (2004). Delayed emesis: moderately emetogenic chemotherapy. Supportive Care in Cancer. 13(2). 104–108. 58 indexed citations

13.

Feyer, Petra, Ernesto Maranzano, Alex Molassiotis, et al.. (2004). Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Supportive Care in Cancer. 13(2). 122–128. 44 indexed citations

14.

Latreille, Jean, Joseph L. Pater, D. Johnston, et al.. (1998). Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 16(3). 1174–1178. 93 indexed citations

15.

Warr, David & Ronald Feld. (1996). The role of supportive care in quality of life. Current Opinion in Oncology. 8(4). 279–283. 2 indexed citations

16.

Warr, David, Peter Venner, Joseph L. Pater, et al.. (1993). A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. European Journal of Cancer. 29(1). 33–36. 29 indexed citations

17.

Levitt, Martin, David Warr, Louise Yelle, et al.. (1993). Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil. New England Journal of Medicine. 328(15). 1081–1084. 52 indexed citations

18.

Sagman, Uri, Ronald Feld, William K. Evans, et al.. (1991). The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.. Journal of Clinical Oncology. 9(6). 954–961. 75 indexed citations

19.

Erlichman, Charles, et al.. (1990). Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.. Journal of Clinical Oncology. 8(2). 337–341. 54 indexed citations

20.

Warr, David. (1978). Evaluating Media in Malawi.. 11(3). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact